Table S1 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma Using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates

Figure S1: MALDI mass spectrometry analysis of YS5-MMAE and Macropa-PEG4-YS5-MMAE revealed an average conjugation of 0.91 Macropa-PEG4 moieties per YS5-MMAE molecule. The disulfide bond reduction process used for MMAE conjugation led to the appearance of multiple peaks in the YS5-MMAE spectrum. For quantifying Macropa-PEG4 conjugation, the doubly charged peak at 75 kDa was used. The difference in peak intensity between YS5-MMAE and Macropa-PEG4-YS5-MMAE was divided by the molecular weight of Macropa-PEG4 to estimate the degree of conjugation.